Abdn.Dev.Cap. (AVC) 시세

This is week 12 since the validation test announcement. JMHO.

One concern I have with attacking our closest allies concerns my investment here in Anavex: will the EMA be generous with an American company's MAA or will it be more inclined to throw up roadblocks? Will our C-level European leadership be an asset at this time? Is the MAA filed out of the Swiss o

ATLnsider I trust that https://find-and-update.company-information.service.gov.uk/company/08717711/filing-history is better informed than you are
Never in my life I hav eever encountered such prejudiced againt reality as the NWBO zealots groupies. Its posts such as your that spread the lies

does seem questionable -- certainly a very impressive result -- but one person only --- abberations do occur

Trump just told him "you're fired, get the hell out"
And for those who attack the messenger without reading contents...why? Afraid to know the truth Or or or
most likely, afraid to lose your pay check?

lol.yep

might be neck and neck if they define nearly identical as +/- 10% difference, or the culture data is a tad worse than ENTA which is in part why they didn't include it in the PR
The ability to combine drugs might give ENTA the edge in some populations who knows
It does seem like a 2 hor

Headed to $1.20 likely previous resistance before selloff

$ALLR Allarity Therapeutics (ALLR): A Biotech Turnaround With FDA Fast-Track Potential

1. The Troubled Past: Poor Leadership and Financial Mismanagement
Allarity Therapeutics was once plagued by severe financial mismanagement, regulatory concerns, and questionable leadership. T

No💹Lose-Lose! $UBQU adds $1.7M✅of long term debt in 12months✅jumping from $1,120,862 to $2,897, 117. Also increased Liabilities from $1,627,303 in 2023 to $4,698,972 in 2024.
https://www.otcmarkets.com/otcapi/company/financial-report/414119/content

“Every year, the Ontario government and its agencies spend $30 billion on procurement, alongside our $200 billion plan to build Ontario. U.S.-based businesses will now lose out on tens of billions of dollars in new revenues. They only have President Trump to blame.”

https://x.com/ford

Clear to see the number of shareholders advocating for the company is climbing steadily.  Getting close here!

$GRLF News-->> Announces Expansion of (COCOA-MGE-Antalya) Flavored Cigar Line.
https://www.accessnewswire.com/newsroom/en/industrial-and-manufacturing/green-leaf-innovations-grlf-celebrates-fdas-decision-to-halt-flavored-c-978444

$GRLF News-->> Announces Expansion of (COCOA-MGE-Antalya) Flavored Cigar Line.
https://www.accessnewswire.com/newsroom/en/industrial-and-manufacturing/green-leaf-innovations-grlf-celebrates-fdas-decision-to-halt-flavored-c-978444

CYCN......................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

Seems pretty much neck to neck on the challenge data. The combo optionality with both L and N might well end up to be a differentiator?

Yea we really need specifics of what smog armor actually does, if anything. Who works there besides Rashad? All the other execs have moved on. Monarch carbon solutions needs a facility or news of forward progress. That's their only means of future revenues through carbon limit licensing agreement an

SGBX .66 merger NAHD preferred at $1 a share

If this company is so great, why do they need someone like TradersTrader to post ALL day long??? Wouldn’t producing something other than a stupid list and a bunch of threats be more effective for shareholders? The more that idiot posts, the less likely people are going to believe the legitimacy of t

Looks like a bloody day coming in the markets.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies (colloquially referred to as cancer vaccines). This is an important step in bringing these promising therapies closer to clinical pra

3 weeks ago Dave said he couldn't imagine it would take this long but that progress was being made, I wonder how he feels today.

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

https://www.globenewswire.com/news-release/2025/02/03/3019337/0/e

HCWB...................MGOL............................MULN..................................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343